Recent studies have demonstrated that GBM with TERT promoter mutation and MGMT promoter unmethylation is associated with decrease sensitivity to radiotherapy and temozolomide (TMZ) treatment (Vuong et al., 2020). The gene discussed is MGMT; the disease is glioblastoma.